HRA Pharma

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, HRA Pharma sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed later-stage tilt top decile by trial count

HRA Pharma: 9 sponsored US clinical trials, none currently recruiting.

HRA Pharma sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 5 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Contraception, with 2 trials.

Top-decile sponsor footprint

HRA Pharma ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 3

Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use

NCT04112095
COMPLETED Phase 2

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

NCT03585712
TERMINATED Phase 3

A Study of Oral Contraception Under Simulated OTC Conditions

NCT03559010
COMPLETED Phase 3

A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

NCT03208985
COMPLETED

Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella

NCT01569737
COMPLETED

Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women

NCT01107106
TERMINATED Phase 2

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

NCT00422201
COMPLETED Phase 3

Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception

NCT00551616
COMPLETED Phase 3

Safety and Efficacy of CDB-2914 for Emergency Contraception

NCT00411684

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 5

Therapeutic Areas

Contraception 2
Emergency Contraception 1

How the HRA Pharma archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase mix: 5 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Contraception (2 trials), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

HRA Pharma: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

HRA Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share HRA Pharma4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
HRA Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

HRA Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this HRA Pharma page

9 registered trials is a research-attention snapshot, not an endorsement of HRA Pharma or any single study.

  • None of HRA Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Contraception is the condition HRA Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Contraception trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

HRA Pharma pipeline card: 9 registered trials from official public datasets.Report a data error.